WHO ICTRP trial
Osimertinib combined bevacizumab in patients with non-small-cell lung cancer…
JPRN-jRCTs071180004 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs071180004 |
|---|---|
| Public title | Osimertinib combined bevacizumab in patients with non-small-cell lung cancer with malignant pleural and/or pericardial effusion -phase II trial- |
| Scientific title | Osimertinib combined bevacizumab in untreated epidermal growth factor receptor mutated non-small-cell lung cancer patients with malignant pleural and/or pericardial effusion -phase II trial- - SPIRAL II Study |
| Primary sponsor | Takayama Koichi |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | advanced/recurrent non-small cell lung cancer (NSCLC) |
| Interventions | Osimertinib 80mg, po once daily and bevacizumab 15mg/kg, iv every 3 weeks are administered until PD as 21 days of 1 cycle (or the meeting of discontinuation criteria). |
| Registration date | Oct 17, 2018 |
| Target size | 30 |
| Secondary IDs | UMIN000028071 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: